Money Transfers Should Be As Easy As Ordering Pizza

 

A new digital payment technology by Toronto-based Nanopay is avoiding the ‘black hole’ of money transfers. Here to explain is Nanopay’s Head of Products Simon Keogh, featured guest on today’s episode of the Software and Technology podcast brought to you by Marketscale.

“When a wire goes across, it goes into a black hole,” Keogh says. “It’s up to someone on the other end to notify me that they’ve received the funds.”

Wire transfers, used by businesses to transfer large sums of money, take several days and are expensive. Checks are no less expensive to process and still one of the most used methods of business to business money transfers.

“Fifty percent of businesses in the United States still pay by check, which is just amazing,” Keogh says.

Alternative solutions, such as Nanopay’s Connect, can not only send money globally at a lower cost than traditional alternatives, but offers a suite of features businesses need: multi-user management, automated payment reconciliation, easy integration, and bank grade security.

“The fact is that I can order a pizza to my home and watch the vehicle drive right to my door, but when I send a wire it takes a few days and I rely on that bank calling me to let me know they’ve received the funds,” Keogh says. “We’re trying to do things faster, better, and cheaper.”

For the latest news, videos, and podcasts in the Software & Electronics Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!
Twitter – @TechMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More